Mast Therapeutics (MSTX) has been under a strong bear grip, hence the stock is down -8.8% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.11% in the past 1 week. The stock has risen by 3.08% in the past week indicating that the buyers are active at lower levels, but the stock is down -8.45% in the past 4 weeks.
Mast Therapeutics, Inc. is up 33.97% in the last 3-month period. Year-to-Date the stock performance stands at -4.31%. The stock has recorded a 20-day Moving Average of 7.72% and the 50-Day Moving Average is 2.79%.
Mast Therapeutics (NYSEMKT:MSTX): The stock opened at $0.41 on Friday but the bulls could not build on the opening and the stock topped out at $0.41 for the day. The stock traded down to $0.40 during the day, due to lack of any buying support eventually closed down at $0.40 with a loss of -0.77% for the day. The stock had closed at $0.41 on the previous day. The total traded volume was 1,258,670 shares.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).